Development of a RVFV ELISA that can distinguish infected from vaccinated animals by McElroy, Anita K et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Virology Journal
Open Access Research
Development of a RVFV ELISA that can distinguish infected from 
vaccinated animals
Anita K McElroy1,2, César G Albariño1 and Stuart T Nichol*1
Address: 1Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, 
USA and 2Department of Pediatrics, Emory University, Atlanta, GA, USA
Email: Anita K McElroy - gsz5@cdc.gov; César G Albariño - bwu4@cdc.gov; Stuart T Nichol* - stn1@cdc.gov
* Corresponding author    
Abstract
Background: Rift Valley Fever Virus is a pathogen of humans and livestock that causes significant
morbidity and mortality throughout Africa and the Middle East. A vaccine that would protect
animals from disease would be very beneficial to the human population because prevention of the
amplification cycle in livestock would greatly reduce the risk of human infection by preventing
livestock epizootics. A mutant virus, constructed through the use of reverse genetics, is protective
in laboratory animal models and thus shows promise as a potential vaccine. However, the ability to
distinguish infected from vaccinated animals is important for vaccine acceptance by national and
international authorities, given regulations restricting movement and export of infected animals.
Results:  In this study, we describe the development of a simple assay that can be used to
distinguish naturally infected animals from ones that have been vaccinated with a mutant virus. We
describe the cloning, expression and purification of two viral proteins, and the development of side
by side ELISAs using the two viral proteins.
Conclusion: A side by side ELISA can be used to differentiate infected from vaccinated animals.
This assay can be done without the use of biocontainment facilities and has potential for use in both
human and animal populations.
Background
Rift Valley fever virus (RVFV) is a member of the family
Bunyaviridae and as such is an enveloped virus that has a
negative stranded RNA genome consisting of three frag-
ments, aptly named S (small), M (medium) and L (large).
The S segment codes for two proteins, a nucleocapsid pro-
tein that coats the viral genome in the virion, and a non-
structural protein (NSs). The NSs protein is especially
interesting, in that it is a filamentous nuclear protein[1],
expressed by a virus that replicates and assembles in the
cytoplasm of infected cells. The NSs protein is known to
be involved in altering the host immune response because
the virulence of viruses lacking a functional NSs is attenu-
ated in mice, and these viruses are potent inducers of IFN
α/β, unlike the wild type (WT) virus [2-4]. The M segment
of the genome codes for two viral glycoproteins that are
on the surface of the virion, as well as a nonstructural pro-
tein (NSm) that has unknown function. Finally, the L seg-
ment of the virus encodes the viral RNA polymerase.
RVFV is a mosquito-borne virus that causes significant
morbidity and mortality in humans and livestock and is
considered to be a bioterrorism threat agent. It was first
identified in the 1930's in Kenya after isolation from a
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sheep in the Rift Valley [5]. It is present throughout Africa,
and has also caused outbreaks in Madagascar off the East-
ern coast of Africa as well as in Yemen and Saudi Arabia
[6].
The virus is transmitted to humans by contact with
infected livestock, usually through the butchering or the
birthing process, or by the bite of an infected mosquito.
Infected individuals typically have a mild disease consist-
ing of fever, malaise, and myalgia; a very small percentage
of these individuals will develop severe disease mani-
fested as hepatitis, encephalitis, retinitis or hemorrhagic
fever, which are the hallmarks of RVFV clinical disease.
The overall fatality rate is estimated at 0.51%. However, in
patients whose clinical illness is sufficiently severe to
bring them to the attention of medical personnel, it has
been reported to be as high as 29%, as was seen in the
Kenya 20062007 outbreak [7].
RVFV is also a significant veterinary pathogen that affects
livestock, such as cattle, goats, and sheep. Up to 90% mor-
tality has been reported in newborn animals and as high
as 30% in adult animals [8]. Consistent with its degree of
pathogenicity in juvenile animals, RVFV is also extremely
abortigenic; 40100% of pregnant animals will abort dur-
ing an outbreak [9]. Furthermore, livestock caretakers are
exposed to virus in the process of caring for sick and dying
animals, especially since amniotic fluid contains high
quantities of virus.
There is a clear need for development of a safe efficacious
vaccine to prevent these naturally occurring large scale
outbreaks of severe disease in livestock and humans in the
affected regions. The sporadic and explosive nature of
these outbreaks makes vaccination control efforts chal-
lenging. It is very difficult in resource limited areas of
Africa or the Middle East to sustain annual vaccination for
a disease that appears infrequently. On the other hand, it
is impossible to effectively vaccinate in the face of a rap-
idly moving ongoing epizootic. In addition, the regula-
tory hurdles and enormous expense to advancement of a
human use vaccine make it unlikely that a product which
targets poorly defined human populations in rural Africa
and the Middle East would get developed. It has been
observed that virus amplification cycles in livestock fre-
quently precede human cases by 34 weeks, and play a crit-
ical role in the early stages of an outbreak. These highly
viremic animals serve as an excellent source of direct con-
tamination of humans, as well as a blood meal source for
mosquitoes which can transmit the virus to humans.
Recently, satellite derived data and rainfall measurements
have proven to be effective predictors of time periods and
geographical regions at high risk of experiencing RVF epi-
zootics [10]. A viable strategy for control of RVF may be to
use these predictive methods for targeted application of
an inexpensive efficacious livestock vaccine which could
prevent livestock epizootics, limit the vertebrate host virus
amplification cycle and thereby also prevent human epi-
demics. Due to export restrictions and other regulatory
issues, acceptance of such a vaccine would require devel-
opment of a companion diagnostic assay that could dif-
ferentiate between infected and vaccinated animals
(DIVA).
There is currently no licensed vaccine available for use in
the US or Europe and vaccine options in Africa and the
Middle East are limited. A formalin inactivated RVFV vac-
cine has limited availability in the US for protection of
military personnel and laboratory workers [11-17]. Two
live attenuated viruses have been tested in various animals
as potential vaccine strains. A mutagen-attenuated strain
(MP12) and the live attenuated Smithburn strain have
been tested in pregnant ewes and lambs, as well as in preg-
nant, fetal, neonatal and adult bovids. The results of these
studies with live vaccines are varied, in some instances
showing no clinical illness and the development of neu-
tralizing antibody titers as well as protection from chal-
lenge [18-21], and in other studies showing the viruses to
be abortogenic and teratogenic [22,23]. Therefore neither
of these virus strains appears to be an ideal candidate for
a vaccine strain because of their questionable safety pro-
files, in addition to their lack of DIVA capability.
In recent years, a reverse genetics system has become avail-
able for RVFV, thereby facilitating studies of viral patho-
genesis and the development of specifically attenuated
vaccine strains [24,25]. This system has been used to gen-
erate viruses that are missing the NSs protein, the NSm
protein, or both. These live attenuated vaccine candidates
provide complete protection with a single administration
in the highly sensitive Wistar-Furth rat model [26].
ΔNSm/ΔNSs virus infected rats demonstrate a strong anti-
body response to the N protein, but as expected, no anti-
body response to the NSs protein. In contrast, rats infected
with WT virus demonstrate an antibody response to both
the N and NSs proteins by immunofluorescence analysis.
The ΔNSm/ΔNSs virus has immense potential as a vaccine
for use in the model proposed above where predictive
methods guide targeted vaccine strategies to prevent live-
stock epizootics. Not only is the exact genetic makeup of
this virus known, since it was generated from cloned
cDNA, but it is more attenuated than the currently availa-
ble attenuated strains, MP12 and Smithburn. The ΔNSm/
ΔNSs virus bypasses the problem of possible reversion to
virulence by having two large deletions, one on the M seg-
ment and one on the S segment of the genome. In addi-
tion, unlike the currently available attenuated strains, the
ΔNSm/ΔNSs vaccine meets the DIVA requirement by vir-
tue of the missing NSs protein.Virology Journal 2009, 6:125 http://www.virologyj.com/content/6/1/125
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In this study, we build upon the observation that infection
with the mutant virus can be distinguished from infection
with the WT virus by immunofluorescence analysis. We
describe the generation of an ELISA that can distinguish
infected from vaccinated animals. This companion assay
can easily be performed in a rudimentary laboratory set-
ting and would be ideal for use the in resource poor coun-
tries where RVFV is prevalent.
Results and Discussion
Cloning, expression and purification of RVFV N and NSs
ELISAs have been used in the past in the diagnosis of RVFV
infection in both humans and livestock [27-31], and these
assays have either used whole cell lysate derived from
infected cells [32] or purified N protein as antigen. Two
viral proteins, N and NSs would be required in order to
develop an ELISA that could distinguish vaccinated from
infected animals. The ORF's of RVFV N and NSs from
strain ZH501 were amplified by PCR and cloned into the
pET20(+)b expression vector with the goal of achieving
soluble expression of His-tagged versions of the proteins
in bacteria. The pET20(+)b vector has a signal sequence at
the N-terminus that directs the expressed protein to the
periplasmic space which should promote folding and
disulfide bond formation and theoretically enhance solu-
bility. However, despite multiple attempts using protocols
for purification of native protein, an appreciable amount
of neither soluble N nor NSs protein were able to be puri-
fied (data not shown).
Successful induction was readily achieved for both the N
and NSs proteins by IPTG induction (Figure 1A). Use of a
denaturing protocol (as described in Methods) for purifi-
cation of His-tagged N and NSs was successful in purifying
the respective proteins (Figure 1). The N and NSs proteins
both eluted most efficiently in the first and second elu-
tions with Bfr E (data not shown, see Methods). Confir-
mation of the identity of the expressed proteins was made
by western blotting using antibodies specific for the
respective protein (Figure 1B and 1C). The induction of N
was very tightly controlled, but as indicated by lane 1 of
Figure 1B, there was some leaky expression of NSs prior to
induction.
Titration of antigens
The N and NSs antigens were serially diluted in PBS and
coated onto EIA plates. A negative control bacterial cell
lysate that had been run through the same purification
protocol was run in parallel with the N and NSs antigens
and the negative lysate OD values were subtracted from
the experimental sample OD values prior to analysis in
order to control for non-specific binding. Two positive
control sera from each of the tested species (goat, rat and
human) were used to determine the optimal amount of
protein to use in the assay. The antigen titration curves for
N and NSs demonstrated linearity at 200 ng/well (corre-
sponding to the part of the curve between 2.0 and 2.5
logs) (Figure 2A, B, C) for all three species, therefore this
was chosen as the concentration to be used in all further
assays. Species specific negative control sera confirmed
the specificity of the assay and secondary only controls
demonstrated the low level of background in these assays.
Analysis of the antibody response in rats and 
demonstration that ELISA can be effectively used to 
distinguish animals infected with wt RVFV from those 
vaccinated with a ΔNSs virus
Four representative rat sera were tested against the two
experimental antigens. These sera were obtained from rats
that had been infected with WT RVFV (samples 1 and 2),
or vaccinated with a ΔNSs virus (samples 3 and 4) [26].
Sera from all animals demonstrated the expected dose
response curves (Figure 3A). As was expected, animals that
were vaccinated with the virus that was missing the NSs
protein did not have an antibody response to the NSs anti-
gen. Therefore these side by side ELISAs were effective at
distinguishing infected from vaccinated animals. These
data were also used to calculate endpoint titers for each
animal that was tested (Figure 3B). The endpoint titer is
the log of the sample sera dilution at which the signal
remains at least two-fold above that of the negative sera
control. The endpoint titer provides a way to normalize
between assays that test sera from different species since
there are varying degrees of background and raw signal
based upon the species being tested. Serum samples from
WT infected rats in general had lower antibody responses
to NSs (as determined by endpoint titers) than to the N
antigen. This phenomenon was also observed with the
other two species as is described below.
Antibody response in goats
In an effort to demonstrate the utility of the assay in a nat-
urally occurring animal host, four representative goat sera
that were obtained from the Jizan province in Saudi Ara-
bia during the RVFV outbreak in 2000 were tested for anti-
body response to N and NSs. Sera from all animals
demonstrated the expected dose response curves (Figure
4A). These data were also used to calculate endpoint titers
for each animal that was tested (Figure 4B). The endpoint
titers for goat sera were similar to those for the rat sera that
were tested. Three of the four animals had a signficantly
greater antibody response to the N protein than to the NSs
protein, which was also observed in the assays done with
rat sera, however all four goats had an antibody response
against both antigens.
This assay would therefore be useful in the diagnosis of
RVFV infection in goats and could be used to distinguish
animals that had been infected with WT virus from ani-
mals that had been vaccinated with the ΔNSs vaccineVirology Journal 2009, 6:125 http://www.virologyj.com/content/6/1/125
Page 4 of 11
(page number not for citation purposes)
strain. Safety and efficacy studies using the ΔNSs vaccine
strain will be initiated in livestock species in the near
future which will allow generation of additional speci-
mens to further characterize the specificity and dynamics
of the N and NSs ELISAs.
Antibody response in humans
Representative human sera were tested to determine the
level of antibody response to the two antigens. Samples 1
and 2 were obtained from naturally occurring RVFV infec-
tions. Sample 3 was from an individual who had been
vaccinated with inactivated RVFV. All human sera that
were used are part of the Special Pathogens Branch refer-
ence collection. All dose response curves demonstrated
the expected progressive slope (Figure 5A). It is interesting
to note that in the naturally occurring infection, an anti-
body response against both N and NSs was detected; how-
ever, in the vaccinated individual there was only an
antibody response to the N protein. All samples had a
similar level of antibody response to the N protein as indi-
cated by the endpoint titers (Figure 5B), and these were
comparable to those observed for rats and goats. The lack
of response of the vaccinated individual to the NSs pro-
tein was expected since viral gene expression is required
for the production of the NSs protein, and this individual
was vaccinated with an inactivated virus.
This assay could prove to be useful in the diagnosis of
human disease especially since it can be easily replicated
without the need for a special containment laboratory to
Expression and purification of the RVFV N and NSs antigens Figure 1
Expression and purification of the RVFV N and NSs antigens. Protein samples were mixed with reducing sample buffer 
and run on SDS PAGE gels as described in Methods. (A) Induction and purification of N and NSs. M: molecular weight maker. 
1: uninduced whole cell lysate from E. coli that was transformed with a plasmid that expressed either the RVFV N or NSs pro-
tein, Lane 2: whole cell lysate from the samples after induction with IPTG, Lane 3: purified N or NSs protein. Gels were trans-
ferred to PVDF membranes and western blotted for either the NSs protein (1B) or the N protein (1C) with human polyclonal 
or mouse monoclonal sera respectively. On each gel lanes 1, 2, and 3 represent uninduced whole cell lysate, induced whole cell 
lysate and purified protein.
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produce antigen. This protein based ELISA would be
much more accessible to researchers and clinicians who
work in regions of the world where this virus is prevalent.
To demonstrate this point, we compared the assay that is
currently being used for diagnosis at the CDC's Disease
Assessment Group of the Special Pathogens Branch [32]
with our assay using human sera (Figure 6). As is demon-
strated using the method of endpoint titers, either antigen
produced comparable results, therefore the N or NSs
based assays would be equally effective at diagnosis, but
would not require BSL-4 for antigen production.
Conclusion
RVFV causes morbidity and mortality in humans and live-
stock that leads to major social and economic conse-
quences in the developing world. The virus is always
Titration of antigens with various sera Figure 2
Titration of antigens with various sera. Antigens were serially diluted and coated onto EIA plates. After overnight binding 
and then blocking, the plates were incubated with a 1:100 dilution of human (A), rat (B) or goat (C) sera and the appropriate 
secondary antibody as described in materials and methods. P is a positive control serum, N is a negative control serum and S is 
a secondary alone control.
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present at endemic levels in the population; however, dur-
ing periods in which human epidemics arise, it has been
observed that they are preceded by epizootics in livestock.
These livestock epizootics serve as an amplification step in
the spread of the virus. Prevention of disease in animals
through the use of a safe and effective vaccine would not
only protect livestock, upon which humans depend for
both survival and their livelihood, but it would also serve
to prevent human disease by breaking the amplification
cycle.
Recent studies done by Bird et al have demonstrated that
a virus can be created using reverse genetics that is missing
one or more viral virulence factors. These viruses are com-
pletely apathogenic in rats and able to provide 100% pro-
tection from challenge with WT virus. The data presented
in this paper expands upon those earlier studies to pro-
vide an easily accessible assay that can be reliably used to
distinguish animals that are infected with WT virus from
animals that have been vaccinated. This differential ability
is important for vaccine acceptance given regulations
restricting movement and export of infected animals in
the affected areas. In addition to indirectly reducing
human morbidity and mortality through the decrease in
epizootics, livestock vaccination would also assist rural
human populations by protecting one of their most valu-
able economic resources.
Methods
Cloning of N and NSs genes
PCR was used to amplify the open reading frame of N and
NSs from the pCAGGS N and NSs vectors respectively
[26]. Primers used for N were as follows: RVFV S Hind III
5' CGA AGC TTG ACA ACT ATC AAG AGC TTG 3'and
Comparison of the N and NSs response in various rat sera Figure 3
Comparison of the N and NSs response in various rat sera. Antigens were coated onto EIA plates as described in 
Methods. After overnight binding and then blocking, the plates were incubated with serially diluted rat sera, and then with anti-
rat HRP. Samples 1 and 2 are from rats that were infected with WT RVFV; samples 3 and 4 are from rats that were infected 
with the ΔNSs virus. Sample N is a negative control rat sera. Figure A demonstrates the dilution curves for each sample. Figure 
B demonstrates the endpoint titers for each antigen for the positive samples.
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RVFV S XhoI 5' CGC TCG AGG GCT GCT GTC TTG TAA
GCC 3'. Primers used for NSs were as follows: RVFV NSs
Hind III 5' CGA ACG TTG ATT ACT TTC CTG TGA TAT C
3' and RVFV NSs XhoI 5' cgc tcg aga tca acc tca aca aat cca
tc 3'. PCR reactions contained 1× AccuPrime Buffer I (Inv-
itrogen), 10 ng plasmid template, 200 nM of each primer,
and 1 ul of AccuPrime Taq DNA Polymerase (Invitrogen).
The following parameters were used for PCR: 94°C for 2
min, then 35 cycles of 94°C for 30 sec, 56°C for 30 sec
and 68°C for 1 min with a final extension of 7 min at
68°C. PCR products were verified by gel electrophoresis
and then prepared for restriction digest using the
QIAquick PCR purificaton kit (Qiagen). PCR products
and target vector pET20(+)b (Novagen) were digested
with Xho I and Hind III in NEB Buffer #2. Digested prod-
ucts were gel purified, and then ligation of pET20(+)b vec-
tor with each of N and NSs were performed overnight
using T4 DNA ligase in 1× ligase buffer (NEB) at 16°C.
Ligations were transformed into competent TOP10 E. coli
(Invitrogen) and plated onto LB with 100 ug/ml ampicil-
lin. Plates were incubated overnight at 37°C and colonies
were selected for analysis. After overnight growth in liquid
culture and miniprep purification, the plasmids were ana-
lyzed by restriction digest with EcoRI to verify correct
insertion. pET20(+)bRVFV NSs cut with EcoRI was
expected to have products of 212 and 4280 bp and
pET20(+)bRVFV N cut with EcoRI was expected to have
products of 668 and 3771 bp. Clones with the correct
restriction digest pattern were sequenced using standard
techniques to verify gene sequence as well as the presence
of the His-tag at the C-terminus of the complete open
reading frame for each protein.
Comparison of the N and NSs response in various goat sera Figure 4
Comparison of the N and NSs response in various goat sera. Antigens were coated onto EIA plates as described in 
Methods. After overnight binding and then blocking, the plates were incubated with serially diluted goat sera, and then with 
anti-goat HRP. Samples 1 through 4 are from naturally infected goats. Sample N is a negative control goat sera. Figure A dem-
onstrates the dilution curves for each sample. Figure B demonstrates the endpoint titers for each antigen for the positive sam-
ples.
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Purification of RVFV N and NSs proteins
pET20(+)bRVFV NSs, pET20(+)bRVFV N or pET20(+)
(empty vector) were transformed into competent BL21
(DE3) E. coli (Novagen) and an isolated colony of each
was selected and grown in liquid LB with 100 ug/ml amp-
icillin until OD600 was between 0.6 and 1.0 then cultures
were stored overnight at 4°C. The following morning, cul-
tures were pelleted for 5 min at 5000 × g. Pelleted bacteria
were resuspended in 10 mL LB medium with 100 ug/ml
ampicillin and innocuated into 500 ml LB with 100 ug/ml
ampicillin. Cultures were incubated at 37°C while shak-
ing until OD600 was 0.6, then expression was induced by
adding IPTG to a final concentration of 0.6 mM and cul-
tures were grown at 37°C for an additional 4 hours. Bac-
teria were pelleted for 10 min at 10,000 × g and stored at
-70°C.
Bacterial pellets were thawed and lysed in 5 ml of Buffer B
(8 M urea, 0.1 M sodium phosphate buffer, 0.01 M Tris-
Cl, pH 8.0) per gram of pellet with the addition of pro-
tease inhibitors (Roche). Lysate was incubated at RT for 1
hour with rocking. Lysate was cleared by centrifugation at
10,000 × g for 30 min at room temperature. Supernate
was stored at -70°C.
Batch purification of His-tagged proteins was achieved by
incubation of 4 ml of cleared lysate with 1 ml of 50%
slurry Ni-NTA His·Bind Resin (Novagen) with rocking at
room temperature for 1 hour. Mix was allowed to settle in
a chromatography column and flow through was col-
lected. Column was washed twice with 4 ml of Buffer C (8
M urea, 0.1 M sodium phosphate buffer, 0.01 M Tris-Cl,
pH 6.3). Elution with Buffers D (8 M urea, 0.1 M sodium
Comparison of the N and NSs response in various human sera Figure 5
Comparison of the N and NSs response in various human sera. Antigens were coated onto EIA plates as described in 
Methods. After overnight binding and then blocking, the plates were incubated with serially diluted human sera, and then with 
anti-human HRP. Samples 1 and 2 are from naturally infected humans. Sample 3 is from a human that was vaccinated with inac-
tivated WT RVFV, and sample N is a negative control human sera. Figure A demonstrates the dilution curves for each sample. 
Figure B demonstrates the endpoint titers for each antigen for the positive samples.
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phosphate buffer, 0.01 M Tris-Cl, pH 5.9) and E (8 M
urea, 0.1 M sodium phosphate buffer, 0.01 M Tris-Cl, pH
4.5) were each performed four times with 1 ml of the
respective buffer.
Samples were analyzed on 412% Bis-Tris gels which were
stained with Simply Blue Safe Stain (Invitrogen).
Western Blotting
Purified fractions of N and NSs were run on 12% Bis-Tris
gels in 1× MES buffer per manufacturer's instructions
(Invitrogen). Gels were transferred to PVDF membranes
using the iBlot Gel Transfer Device (Invitrogen). Blots
were blocked in blocking buffer (5% skim milk in TBS
with 0.1% tween 20) for 1 hour at RT. The blots were then
placed in primary antibody diluted in blocking buffer and
incubated for 1 hour at RT. Mouse monoclonal against the
N protein was used at 1:500 and was generated by the Spe-
cial Pathogens Branch, and human polyclonal was used at
1:1000 and is a reference sample from the Special Patho-
gens Branch. Blots were washed in TBST (1× TBS with
0.1% tween 20) 3 times for 5 min each then placed in sec-
ondary antibody; goat anti-mouse HRP (KPL) or goat
anti-human HRP (Jackson ImmunoResearch) diluted
1:20,000 in blocking buffer for 1 hour at RT. Blots were
again washed 3 times in TBST for 5 min each. Blots were
placed in Supersignal West Dura Reagent (Pierce) for 5
min and signal was detected on an Alpha Innotech
FluroChemHD2 imager.
Enzyme linked immunosorbant assay
Purified N, purified NSs, negative control bacterial cell
lysate, whole cell lysate from RVFV infected Vero E6 cells,
or negative control cell lysate from uninfected Vero E6
cells were diluted in PBS and allowed to absorb overnight
onto 96 well EIA plates (Costar). N and NSs antigens were
applied to EIA plates either in serial dilutions for antigen
titration experiments, or at a concentration of 200 ng/well
for serum dilution experiments. Negative control bacterial
cell lysate was applied to a separate plate at an equivalent
volume. Whole cell lysates from RVFV infected Vero E6
cells or uninfected Vero E6 cells were used at 1:2000 per
established diagnostic protocols. Plates were blocked in
1× blocking buffer (5% skim milk, 5% fetal bovine serum,
and 0.1% tween 20 in 1× PBS) at 37°C for 1 hour. Plates
were then incubated with primary antibodies at specified
dilutions in blocking buffer for 1 hour at 37°C. Plates
were washed 3 times in PBST (1× PBS with 0.1% tween
20) and then incubated with goat anti-rat HRP
(1:10,000), bovine anti-goat HRP (1:10,000), or goat
anti-human HRP (1:10,000) (Jackson ImmunoResearch),
diluted in blocking buffer for 1 hour at 37°C. Plates were
washed 3 times in PBST prior to the addition of ABTS sub-
strate used according to the manufacturer's instructions.
Reactions were stopped with the addition of 1% SDS and
read at 405 nM. All samples were run in duplicate and
averages were used in the analysis. Absolute values
obtained from negative control lysates were subtracted
N and NSs derived assays are comparable to the current gold standard assay using RVFV infected cell lysate Figure 6
N and NSs derived assays are comparable to the current gold standard assay using RVFV infected cell lysate. 
RVFV infected cell lysate at 1:2000 dilution or N or NSs at 200 ng/well were coated onto EIA plates and allowed to absorb 
overnight. The assay was carried out as described in Methods. Endpoint titers against each antigen from a human case that was 
naturally infected (P) and from a human that was vaccinated (V) are shown.
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from values obtained from the experimental antigen prior
to analysis to control for non-specific binding.
Abbreviations
The following abbreviations were used in the manuscript:
RVFV: Rift Valley Fever Virus; ELISA: Enzyme Linked
Immunosorbant Assay; EIA: Enzyme Immuno Assay; PBS:
Phosphate Buffered Saline; HRP: Horseradish Peroxidase;
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